HOTH: Hoth Therapeutics Inc. Company Short-Term Debt

High competition in dermatology and a limited budget are forcing Hoth Therapeutics, Inc. (HOTH) to risk its capital, which is reflected in the current liabilities metric; this figure equals 0.00. Meanwhile, FDA patent protection guarantees the exclusivity of its developments, and the unique drug HT-001 provides the company with significant pricing power in the oncodermatology niche due to the low elasticity of demand for treatment.

To assess the fundamental stability of an asset, an investor must analyze the volume of liabilities maturing within one year, which determine the risk of a cash gap during liquidity shortages. By analyzing the dynamics of short-term credit obligations, one can evaluate the ability of Hoth Therapeutics, Inc. (HOTH) to fund costly R&D developments in oncology and dermatology without imposing a critical debt burden on capital.